Research & Development


  • Teresa Bitetti Takeda Oncology
    Image attribution tooltip
    Diego Camargo/PharmaVoice
    Podcast

    Woman of the Week: Takeda Oncology’s Teresa Bitetti

    Upon joining Takeda Pharmaceuticals as president of the global oncology unit, Teresa Bitetti had two important goals: to transform the business and create greater synergies between commercial and R&D operations.

    By Aug. 17, 2022
  • Pill
    Image attribution tooltip
    Liudmila Chernetska via Getty Images

    Inventing the COVID vax pill: a matter of convenience and durability

    Recent data from Vaxart’s phase 1 trial of its COVID-19 inoculation pill shows potential.

    By Kelly Bilodeau • Aug. 17, 2022
  • George Magrath wears blue scrubs and sits over a patient.
    Image attribution tooltip

    Permission granted by George Magrath. 

    The CEO in the ophthalmologist’s coat

    In balancing two roles — Lexitas CEO and practicing physician — George Magrath brings a patient-first perspective to developing and advancing eye treatments.

    By Alexandra Pecci • Aug. 16, 2022
  • Nasal spray
    Image attribution tooltip
    Evgenyi_Eg via Getty Images

    Right under our noses: Could COVID-19 vaccines be better as nasal spray?

    Nasal vaccines under development by Codagenix, Xanadu Bio and others have the potential to finally help reduce virus transmission and breakthrough infections.

    By Kelly Bilodeau • Aug. 16, 2022
  • Seen from behind, a clinician is using a cell phone and checking a patient's electronic health record on a laptop.
    Image attribution tooltip
    iStock via Getty Images
    Q&A

    How real world evidence is impacting rare disease drug development

    https://www.gettyimages.com/detail/photo/woman-at-home-using-cell-phone-and-checking-ehr-royalty-free-image/1249041723?adppopup=true

    By Kim Ribbink • Aug. 9, 2022
  • A baby harp seal pup lays on ice in the White Sea.
    Image attribution tooltip
    iStock via Getty Images

    Turning harp seal contraceptives into a ‘new genre’ of cancer treatments

    With Andrew Hall at its helm, IMV has evolved an animal contraceptive into a unique drug delivery platform aimed at creating targeted cancer immunotherapies for humans.

    By Alexandra Pecci • Aug. 9, 2022
  • monkeypox vax
    Image attribution tooltip
    Mario Tama via Getty Images

    The ‘alarming’ spread of Monkeypox — by the numbers

    With vaccine and treatment supplies constrained, the virus is becoming ‘less predictable.’

    By Aug. 8, 2022
  • A hand picks a blue figurine out of rows of similar wooden figurines.
    Image attribution tooltip
    Ivan Balvan via Getty Images

    Editas, Real Chemistry and Compass blaze new trails with pivotal C-suite hires

    How these latest executive personnel changes are impacting the industry. 

    By Aug. 3, 2022
  • A collage of pnk, blue and orange bacteria-like blobs float around against a dark blue background.
    Image attribution tooltip
    iStock via Getty Images

    Taking probiotics where they’ve never gone before

    How Seed Health is transforming the microbiome therapeutic market with its pharma-focused drug development approach.

    By Aug. 2, 2022
  • A physician in a white scrubs assists a blue-shirted patient.
    Image attribution tooltip
    iStock via Getty Images

    ‘Death by 1,000 cuts:’ How emerging tech could change the journey for ALS patients

    EverythingALS aims to speed drug development through improved diagnostics.

    By Kelly Bilodeau • Aug. 2, 2022
  • Artifical intelligence
    Image attribution tooltip
    Olemedia via Getty Images
    Q&A

    How a speech analysis tool could transform diagnosis and research for Alzheimer’s and beyond

    WinterLight’s machine learning platform assesses speech to more accurately identify neurodegenerative diseases.

    By Kim Ribbink • Aug. 1, 2022
  • A nurse in green scrubs puts a smart watch on a patient in a grey, blue and orange striped shirt.
    Image attribution tooltip
    Giuseppe Lombardo via Getty Images
    Q&A

    Personalized data could bring PhysIQ to the forefront of clinical trial evolution

    The digital medicine company’s chief strategy officer, John Varaklis, explains how its analytic predictive platform could lead to safer and quicker clinical trials.

    By July 28, 2022
  • A person points a pen at a computer with a green line graph. A blurred computer in the background shows other graphs.
    Image attribution tooltip
    iStock via Getty Images

    What’s next for Biogen? Here’s what executives are saying

    A trickling launch for Aduhelm and a middling earnings report give Biogen executives a lot to talk about. Is there hope?

    By July 27, 2022
  • long covid
    Image attribution tooltip
    Lisa Maree Williams via Getty Images
    Q&A

    Lupus discovery lends clues to the fight against long COVID

    So far, pharma has yet to provide an answer for long COVID. But award-winning lupus research by Yale professor Akiko Iwasaki could help lead the way.

    By Kelly Bilodeau • July 27, 2022
  • Katie Williams head shot
    Image attribution tooltip
    Diego Camargo/PharmaVoice
    Podcast

    Woman of the Week: Applied BioMath's Katie Williams

    The 2022 president of Women in Bio is equal parts math and gender parity evangelist. 

    By July 27, 2022
  • newborn screening
    Image attribution tooltip
    Stock via Getty Images

    The earlier the better: New consortium leverages infant screening to accelerate treatment

    Inozyme Pharma has joined a genomic sequencing program developing a novel rapid test for 388 genetic diseases.

    By Kim Ribbink • July 25, 2022
  • Neuron
    Image attribution tooltip
    koto_feja via Getty Images

    A 'total waste'? Drug developers worry if two decades of Alzheimer's research were pointed at the wrong targets

    The latest trial failures in Alzheimer's have shown cracks in the foundation of ingrained theories like amyloid plaque clearance. What will it take to move forward?

    By July 25, 2022
  • A man walks out of the Pfizer world headquarters building.
    Image attribution tooltip
    Chris Hondros / Staff via Getty Images
    Q&A

    Behind Pfizer's new quest to target a 'transformation' in pharma

    A combined venture with Roivant — called Priovant Therapeutics — is looking to be a forerunner in the burgeoning autoimmune disease market.

    By Kelly Bilodeau • July 25, 2022
  • A red Moderna sign hangs on the front of a beige building.
    Image attribution tooltip
    Maddie Meyer / Staff via Getty Images

    Moderna's next vax target? A little-known cause of birth defects

    How the mRNA-based biotech is developing the first-ever prophylactic for a devastating virus.

    By July 21, 2022
  • A person wearing a purple latex glove holds a petri dish with pink and red spots vertically with their thumb and index finger.
    Image attribution tooltip
    iStock via Getty Images

    By the numbers: The rising danger of superbugs

    A look at how the COVID-19 pandemic exacerbated one of the world’s greatest public health concerns.

    By July 20, 2022
  • MeiMei Hu Headshot
    Image attribution tooltip
    Diego Camargo/PharmaVoice
    Podcast

    Woman of the Week: Vaxxinity's Mei Mei Hu

    Mei Mei Hu is looking to lead a third biologic ‘revolution’ by developing vaccines for chronic diseases.

    By July 20, 2022
  • R&D costs
    Image attribution tooltip
    ADragan via Getty Images

    Biotech R&D spending has skyrocketed, and so have opportunities for savings

    With R&D costs on the rise, biotechs are embracing new strategies and technologies to make spending more efficient.

    By July 19, 2022
  • John LaMattina
    Image attribution tooltip

    Permission granted by John LaMattina

    Pfizer's former R&D head takes on drug pricing misconceptions in new book

    John LaMattina has something to say about the industry — and he hopes patients are listening.

    By July 19, 2022
  • A person holds a magnet pointed at multi-colored wooden figures of people sitting on dark wood-grain table.
    Image attribution tooltip
    iStock via Getty Images

    Making moves: Agios, BeiGene, Biocom California and more announce new key hires

    The latest executive personnel changes from around the industry.

    By July 18, 2022
  • gene therapy
    Image attribution tooltip
    Stock via Getty Images
    Q&A

    First 90 Days: Anjarium Biosciences' Stephen Yoo

    The incoming CEO aims to build on the buzz around the company’s leading-edge gene therapy tech.

    By Kim Ribbink • July 15, 2022